Effect of sodium‐glucose cotransporter 2 inhibitor, empagliflozin, and α‐glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes

Objective We investigated the effects of sodium‐glucose cotransporter 2 inhibitor, empagliflozin, and α‐glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes (T2DM). Methods Empagliflozin (OLETF‐EMPA) or voglibose (OLETF‐VOG) was administered to Otsuka Long‐Evans Tokushima fatty (OLETF) rats once daily for 12 weeks. Control Long‐Evans Tokushima Otsuka (LETO) and OLETF (OLETF‐C) rats received saline. Results...